 | | Vol. 11.40 – 15 October, 2020 |
| |
|
|
| Scientists demonstrated a unique role for liver in modulating the pathogenesis of leukemic disease and suggest that the hepatic microenvironment may protect leukemia cells from chemotherapeutic challenge.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Overexpression of activated ERBB2 in cardiomyocytes presented an epithelial-mesenchymal transition-like regenerative response manifested by cytoskeletal remodeling, junction dissolution, migration and ECM turnover.
[Nature Cell Biology] |
|
|
|
| Investigators used single cell RNA-sequencing of patient tumors to identify three prognostic surface markers (LYPD3, TACSTD2, and LY6D) which correlated with nuclear myocardin-related transcription factor (nMRTF) and resistance to SMO inhibitors. The nMRTF cell state resembled transit-amplifying cells of the hair follicle matrix, with AP-1 and TGFß cooperativity driving nMRTF activation.
[Nature Communications] |
|
|
|
| A 2D nanosheet‐based catalytic nanomotor with chemotaxis behavior was developed for enhanced drug delivery toward the tumor microenvironment. The nanomotors were constructed via a facile one‐pot method and exhibited ultrathin monolayer nanosheet morphology.
[Small] |
|
|
|
| Scientists used a knock-in mouse line, a genetic model for breast cancer and metastasis, a syngeneic melanoma lung colonization model, and orthotopic injection of E0771 breast cancer cells to show that alternative forms increased the diversity of Angiopoietin-2 function.
[Cancer Research] |
|
|
|
| The authors showed that Mlc1 was expressed in human stem-like glioblastoma (GBM) cells and was linked to the development of primary and recurrent GBM.
[Oncogene] |
|
|
|
| Angiopoietin-like protein 2 (ANGPTL2) secreted from intestinal subepithelial myofibroblasts drove generation of Ly6Chigh immunostimulatory macrophages via NF-κB signaling to promote CD4+ Th1 cell responses that established an anti-tumor microenvironment during injury-induced intestinal tumorigenesis.
[Oncogene] |
|
|
|
| The authors revealed that TGFβ1 could significantly upregulate miR-455 and miR-210 expression in synoviocytes. The upregulated miRNAs could be secreted into the extracellular environment and prevent cartilage degeneration.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Researchers found a strong positive correlation between β-catenin and TGF-β2 proteins in women with adenomyosis. Treatment with pirfenidone, a TGF-β inhibitor, increased E-cadherin expression and reduced cell invasiveness in Ishikawa cells with nuclear β-catenin.
[Experimental and Molecular Medicine] |
|
|
|
| The authors report on the development of an in situ-forming hydrogel of collagen type I crosslinked via multi-functional polyethylene glycol (PEG)-N-hydroxysuccinimide and characterize its biophysical properties and regenerative capacity both in vitro and in vivo.
[Scientific Reports] |
|
|
|
| Staining of different types of cartilage results in differential matrix staining, thus showing the sensitivity of this staining method to relatively small differences in ECM composition. An extreme example of this sensitivity was provided by the staining of chondrosarcomas that resulted in a wide spectrum of shades of colors in the tumoral intercellular matrix, reflecting the heterogeneity of tumor ECM composition.
[Scientific Reports] |
|
|
|
| Researchers developed a murine-based engineered cardiac tissues model to investigate cardiac injury produced by advanced glycation end-products (AGEs). One finding was that AGEs treatment significantly increased the markers of fibrosis (TGF-β, α-SMA, Ctgf, Collagen I-α1, Collagen III-α1, and Fn1) and hypertrophy.
[Acta Pharmacologica Sinica] |
|
|
|
|
| The authors focus on how tumor and tumor-associated stromal cells deposit, biochemically and biophysically modify, and degrade tumor-associated ECM.
[Nature Communications] |
|
|
|
|
| Phenomic AI announced the official launch of the company with US$6 million seed financing. The proceeds of the financing will support preclinical studies for two validated cancer drug targets in the tumor stroma, discovered with the company’s platform as well as discover and advance additional drug targets into the company’s pipeline.
[Phenomic AI (Businesswire, Inc.)] |
|
|
|
| NOXXON Pharma N.V. announced that all three patients of the second dose cohort have been enrolled into the brain cancer clinical trial testing CXCL12 inhibitor, NOX-A12, and have already received the planned initial treatment. The Phase I/II clinical study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external beam radiotherapy in newly diagnosed brain cancer patients.
[Noxxon Pharma N.V.] |
|
|
|
|
| November 25 – November 27
Virtual |
|
|
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| | Medical University of Vienna – Vienna, Austria |
|
|
|
| | The Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Moores Cancer Center, UC San Diego – La Jolla, California, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
